Category Archives: General Cynicism

Rating of U.S. health Care: Commonwealth Fund

The Commonwatlth Fund’s review of U.S. health care provides assessments of our non-system’s efficiency, equity, access and quality.

Some good news can be found in an exception to the overall pattern of U.S. performance: rapid progress on quality metrics that have been the focus of national initiatives and public reporting efforts. Hospitals, nursing homes, and home health care agencies are showing marked improvement in patient treatment and outcomes for which data are collected and reported nationally on federal Web sites and as part of improvement campaigns. There has also been significant improvement in the control of high blood pressure, a measure that is publicly reported by health plans; increasingly, physician groups are being rewarded for improving their treatment of this and other chronic conditions. Better management of chronic diseases also has likely contributed to reductions in rates of avoidable hospitalizations for certain conditions, though rates continue to vary substantially across the country.

Of great concern, access to health care significantly eroded since 2006. As of 2010, more than 81 million working-age adults—44 percent of those ages 19 to 64—were uninsured during the year or underinsured, up from 61 million (35%) in 2003. Further, the U.S. failed to keep pace with gains in health outcomes achieved by the leading countries. The U.S. ranks last out of 16 industrialized countries on a measure of mortality amenable to medical care (deaths that might have been prevented with timely and effective care), with premature death rates that are 68 percent higher than in the best-performing countries. As many as 91,000 fewer people would die prematurely if the U.S. could achieve the leading country rate.

The summary also notes the cost burden and the lack of improvement in many health system indicators:

such as preventive care, adults and children with strong primary care connections, and hospital readmissions—likely stems from the nation’s weak primary care foundation and from inadequate care coordination and teamwork both across sites of care and between providers. These gaps highlight the need for a whole-system approach, in which performance is measured and providers are held accountable for performance across the continuum of care.

A nice chart shows some of the savings that would accrue if we actually had a system:



Medicynical Note: We spend more and have worse health care. Only in the U.S.


Our inefficient Non-System of Health Care: We’re Number 1

Administrative costs in health care are a silent epidemic. Our inefficiency is costly to patients, providers, insurers, and government.

Ewe Reinhardt observes:

In many ways, our health care system mirrors our tax code — especially in its financing and health insurance facets. These can be made so complex and have been made so complex in the health care system in the United States that many decision makers in health care — patients, physicians, hospitals, employers and so on — need in-house or external consultants to find their way through the maze.

and:

Consulting firms help physicians bill private and public insurers or help patients submit claims to insurers after an illness. Legions of insurance brokers help prospective clients through the maze of the nongroup or small-group health insurance market. Large employee-benefit consulting firms, helping large companies, establish what amount, in effect, to analogues of the health-insurance exchanges in the Affordable Care Act, and many more consultants of many stripes are involved.

Medicynical Note: Yes the U.S. has the number 1 health care system in the world–it’s the most inefficient by far.


Drug Prices for Indigent Medicare Patients: The Same As Medicaid or Cost plus?

The New England Journal of Medicine (NEJM) (Oct. 12, 2011) looks at the proposal to require drug companies to offer low income Medicare beneficiaries the same prices given Medicaid recipients:

Seems like a reasonable money saving idea but:

Reducing Part D payments for low-income beneficiaries, it is argued, could undermine incentives for the pharmaceutical industry to invest in research and development, as well as create illusory savings by shifting drug costs to other parties. In considering the wisdom of such deficit-reduction proposals, it’s important to consider how well the market is working for Part D and whether there are important inefficiencies that can be eliminated, resulting in budget savings.

It is pointed out however that the market doesn’t seem to work well with the indigent elderly who most often of the medicare group have multiple chronic conditions (30% of the group) and spends more on drugs than others in the medicare group.

It concluded that:

The approach obtains savings without undermining incentives for developing important new medical treatments. The anticipated side effects would be outweighed by the size of the estimated budget gains. This is as close to a win–win solution as we can get.

Medicynical Note: Put pressure on drug companies to offer more affordable drugs, why that may be Un-American. Consider that drug companies spend more on marketing than research; pay nothing to the government for drugs developed from government funded research; all have increased their prices and revenue by incredible amounts during a recession/depression.

Big PHarma will oppose this initiative preferring that we continue to pay more for drugs than any other industrialized country in the world. That’s really Un-American.


Cancer Treatment Costs a Lot

The Washington Post notes the “hefty cost” of cancer treatment even for those with insurance.

Recent research spells out what patients are facing. A study by the Agency for Healthcare Research and Quality estimated that between 2001 and 2008, 13.4 percent of adults younger than 65 who had cancer spent more than 20 percent of their income on health care, including premiums. That compared with 9.7 percent of people with other chronic conditions and just 4.4 percent of those with no chronic conditions.

The article goes on to note the the increased bankruptcy rate among patients –over 6 times the baseline rate over 5 years.

ASCO the American Society of Clinical Oncology in the same article is noted to recommend :

The American Society of Clinical Oncology encourages oncologists to discuss treatment costs with patients. But that’s easier said than done, say some oncologists. More than half of the income of many oncology practices comes from administering the drugs they prescribe, says Ramsey, so oncologists are not entirely disinterested parties. In addition, the timing is often tough. Patients are “already scared and they have cancer,” he says.

Medicynical Note: It appears from their pricing of medications that drug companies have a sliding scale. The more life threatening the illness, the more the drug costs–whether or not it has a significant effect on the disease’s course

Another factor in the cost of cancer treatment, or any drug treatment purchased in the U.S., is that we pay more by 30%, for the exact same drug than other countries’ citizens. It’s a fact.

What’s amazing is that we tolerate the discriminatory behaviour of drug companies and pay the increased price.


Vitamin E and Selenium May Increase the Risk of Prostate Cancer

The October 12 Journal of the American Medical Association reports a slight increase in the risk of prostate cancer from vitamin E and selenium. The increase from selenium is not considered statistically significant. Vitamin E’s increase just met the criteria and is considered more likely to be real. This increase in risk, for both agents, is important in that they were being evaluated as preventatives. They obviously don’t work.

This report includes 54 464 additional person-years of follow-up and 521 additional cases of prostate cancer since the primary report. Compared with the placebo (referent group) in which 529 men developed prostate cancer, 620 men in the vitamin E group developed prostate cancer (hazard ratio [HR], 1.17; 99% CI, 1.004-1.36, P = .008); as did 575 in the selenium group (HR, 1.09; 99% CI, 0.93-1.27; P = .18), and 555 in the selenium plus vitamin E group (HR, 1.05; 99% CI, 0.89-1.22, P = .46). Compared with placebo, the absolute increase in risk of prostate cancer per 1000 person-years was 1.6 for vitamin E, 0.8 for selenium, and 0.4 for the combination.

Medicynical Note: This is not stunning news as vitamin and mineral supplements have little efficacy–unless there is dietary deficiency. Perhaps our pill popping culture will take note.


Dietary Supplements: An Illusion that became a Delusion

The use of vitamin supplements have become almost a religious belief in our culture. We bought the notion that If some is good, more must be better.

But, there is little evidence of efficacy of vitamins in healthy people who eat a balanced diet. There is however increasing evidence of harm.

After adjustment for multiple potential confounders, use of multivitamins and vitamin B6, folic acid, iron, magnesium, zinc, and copper supplements was associated with greater all-cause mortality through 19 years of follow-up (HRs 1.06 to 1.45), according to Jaakko Mursu, PhD, of the University of Eastern Finland in Kuopio, and colleagues.

Use of a daily calcium supplement, on the other hand, was associated with a lower risk of death (HR 0.91, 95% CI 0.88 to 0.94), the team reported in the Oct. 10 issue of the Archives of Internal Medicine.

And:

“We cannot recommend the use of vitamin and mineral supplements as a preventive measure, at least not in a well-nourished population,” they wrote. “Those supplements do not replace or add to the benefits of eating fruits and vegetables and may cause unwanted health consequences.”


Why Drugs Cost So Much: All Animals Are Equal but Some are More Equal Than Others

The drug industry is lobbying furiously:

The primary trade group for the pharmaceutical industry spent $4.7 million in the second quarter lobbying the federal government on prices that federal health programs pay for prescription medicines and on other issues including patents, drug shortages and reimportation of drugs, according to a quarterly disclosure report.

And:

lobbied on implementation of aspects of the 2010 health care overhaul, including prices and rebates for drugs bought through the Medicare program, strengthening Medicare anti-fraud measures and eliminating an independent payment advisory board meant to hold down Medicare spending.

The article also highlights those former government officials currently lobbying their former colleagues on this issue.

Medicynical Note: Read the article. PhRMA opposes anything that will decrease drug prices. Consumer interest, value, access to less expensive drugs all are opposed by this group.

Since our esteemed Supreme Court ruled that corporations are citizens with equal rights to individuals, it appears that George Orwell’s truism from Animal farm has finally come to fruition. “All animals are equal but some are more equal than others.”


Money Flow, Medicare, Private Insurance, Waste

Interesting Economix by Uwe Reinhardt on money flow in health care:

He notes:

In fairness, it must be added that traditional Medicare basically sets prices and then just pays bills. It makes no active attempt to manage care (utilization controls, disease management, coordinating care and so on), because it has not been allowed by Congress to do so. It is almost as if Congress did not want traditional Medicare to be a prudent purchaser of heath care for the elderly. (Medicynical emphasis)

From the viewpoint of prudent purchasing, most economists would probably judge these prices too low. On the other hand, the fact that traditional Medicare just pays bills more or less passively may be precisely the reason that it is still so popular among the elderly. Traditional Medicare still offers beneficiaries completely free choice of providers and therapy — a degree of freedom that many younger Americans in insurance plans with limited networks of providers no longer enjoy.

Medicynical Note: Until we approach the issue of value in medicine (What works? Bang for the buck?) we’ll have the most expensive least efficient health care non-system in the world. What’s bugging us, the US, now is how to get to such a system.

Is health care part of the package of being a US citizen? Providing Medicare to the elderly and many with chronic illness implies such a commitment. Does required access to ER care for all, whether they can pay or not, point to a civic responsibility to assure access to care to the rest of the population?

If our republican friends really believe that health care is not a “right” then a large swath of citizenry are going to be in trouble as republicans follow through on this philosophy. Interestingly these rightist purists for some reason tout ER access for all as adequate health care in our non-system. Why they would choose the most expensive, least efficient care in the world as their means of providing health care is unknown.

If there is an explicit right to health care in our country, more efficient ways to provide it must be found. It should assure affordable care to citizens, including the elderly and those with illnesses. One problem has been that private insurers, ironically, want little to do with either of those populations.


America’s Ass-Backward Non System of Health Care — Controlling ER visits

You may have heard from Rush Limbaugh and others on the right that we already have a system of health care. That is, emergency room care is available to everyone whether they can pay or not.

What’s not said is that this care is the least efficient and most expensive in the world. And that these unpaid costs are ultimately borne by the local hospital, other patients and other insurers–private as well as Medicare. This raises the cost of health care to all of us. I can’t imagine any thinking person would think this an adequate solution–except as noted above.

Now Washington State, offers a brilliant solution to the problem, by limiting ER visits to 3/year for people covered with Medicaid.

The trouble is all in how you define an emergency.

And:

If a condition is left unspecified, that means it turned out to not be connected to a more dangerous ailment such as a heart attack or stroke. But doctors say that result can’t be known until patients are treated.

“Do (patients) know the difference necessarily between heartburn, heart attack, a blood clot in my lungs and a sore rib?” asked Dr. Stephen Anderson, president of the American College of Emergency Physicians’ state chapter. “These people shouldn’t be sitting at home trying to self-diagnose.

Medicynical Note: Rather than provide outpatient care for these patients as an alternative to ER care and thereby encourage use of more cost effective facilities, we simply cut off all access. Amazing.

This non solution leaves the ER’s and hospitals with a financial problem. Medicaid patients with chest pain that is non cardiac and other problems that turn out not to be “serious” will not be covered by Medicaid . Other patients without any insurance will continue to use ER’s and accrue bills that will not be paid. The cost of their care will still be passed through to other patients and insurers.

The solution solves nothing and simply avoids facing the fundamental issue in our non-system of care–that it is not a system.

Too Much Health Care? Primary Care Physicians Views

A recent Archives of Internal Medicine study of primary care physicians noted:

Forty-two percent of US primary care physicians believe that patients in their own practice are receiving too much care; only 6% said they were receiving too little. The most important factors physicians identified as leading them to practice more aggressively were malpractice concerns (76%), clinical performance measures (52%), and inadequate time to spend with patients (40%). Physicians also believe that financial incentives encourage aggressive practice: 62% said diagnostic testing would be reduced if it did not generate revenue for medical subspecialists (39% for primary care physicians).

It was also noted in a Reuter’s piece about the Archives article that:

Four in 10 also believed that other primary care physicians would order fewer tests if those tests didn’t provide extra income. (Of course, just three percent thought that financial considerations influenced their own practice style.)

“I’m not saying that physicians do tests in order to make money — there is a potential to be a real cynic here — but I think that the reimbursement model for most healthcare encourages utilization in a variety of way,” Sirovich said.

Medicynical Note: It’s not cynical to acknowledge reality.